GW&K Investment Management LLC Sells 280,750 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

GW&K Investment Management LLC lessened its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 16.1% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,464,891 shares of the biopharmaceutical company's stock after selling 280,750 shares during the quarter. Halozyme Therapeutics makes up about 0.9% of GW&K Investment Management LLC's holdings, making the stock its 17th largest position. GW&K Investment Management LLC owned approximately 1.19% of Halozyme Therapeutics worth $93,475,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of HALO. Penserra Capital Management LLC bought a new stake in shares of Halozyme Therapeutics in the first quarter valued at $125,000. Bessemer Group Inc. raised its stake in shares of Halozyme Therapeutics by 62.9% in the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 207 shares during the period. D. E. Shaw & Co. Inc. raised its stake in shares of Halozyme Therapeutics by 171.2% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company's stock valued at $39,750,000 after buying an additional 524,802 shares during the period. Fifth Third Bancorp raised its stake in shares of Halozyme Therapeutics by 29.4% in the first quarter. Fifth Third Bancorp now owns 10,017 shares of the biopharmaceutical company's stock valued at $639,000 after buying an additional 2,276 shares during the period. Finally, GAMMA Investing LLC raised its stake in shares of Halozyme Therapeutics by 199.0% in the first quarter. GAMMA Investing LLC now owns 2,802 shares of the biopharmaceutical company's stock valued at $179,000 after buying an additional 1,865 shares during the period. Institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Trading Down 2.4%

NASDAQ HALO opened at $56.45 on Monday. The stock has a 50-day moving average of $54.29 and a 200-day moving average of $57.34. The firm has a market cap of $6.96 billion, a PE ratio of 15.01, a price-to-earnings-growth ratio of 0.38 and a beta of 1.15. The company has a current ratio of 8.39, a quick ratio of 7.30 and a debt-to-equity ratio of 3.13. Halozyme Therapeutics, Inc. has a 1-year low of $42.01 and a 1-year high of $70.51.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 EPS for the quarter, beating analysts' consensus estimates of $0.98 by $0.13. The business had revenue of $264.86 million during the quarter, compared to analyst estimates of $231.21 million. Halozyme Therapeutics had a return on equity of 136.91% and a net margin of 44.76%. Halozyme Therapeutics's quarterly revenue was up 35.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.79 EPS. As a group, sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on HALO. JPMorgan Chase & Co. lifted their price target on Halozyme Therapeutics from $58.00 to $60.00 and gave the company a "neutral" rating in a research report on Wednesday, July 16th. The Goldman Sachs Group began coverage on Halozyme Therapeutics in a research report on Thursday, July 10th. They issued a "neutral" rating and a $55.00 price target for the company. HC Wainwright reiterated a "buy" rating and issued a $72.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, May 29th. Leerink Partnrs cut Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Tuesday, May 13th. Finally, Wells Fargo & Company boosted their target price on Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a research report on Wednesday, May 7th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $62.70.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 4,497 shares of the company's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $60.37, for a total transaction of $271,483.89. Following the transaction, the director owned 28,611 shares in the company, valued at approximately $1,727,246.07. This represents a 13.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Helen Torley sold 20,000 shares of the company's stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $56.43, for a total value of $1,128,600.00. Following the transaction, the chief executive officer owned 733,719 shares in the company, valued at $41,403,763.17. This trade represents a 2.65% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 64,497 shares of company stock worth $3,533,884 in the last quarter. Company insiders own 2.90% of the company's stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.